Rankings
Publications
Sources
Publishers
Scholars
Organizations
About
Login
Register
Home
Publications
Data from Prognostic Utility of Anti-EBV Antibody Testing for Defining NPC Risk among Individuals from High-Risk NPC Families
Home
Publications
Data from Prognostic Utility of Anti-EBV Antibody Testing for Defining NPC Risk among Individuals from High-Risk NPC Families
Data from Prognostic Utility of Anti-EBV Antibody Testing for Defining NPC Risk among Individuals from High-Risk NPC Families
KY
Kelly J. Yu
Kelly J. Yu
WH
Wan-Lun Hsu
Wan-Lun Hsu
RP
Ruth M. Pfeiffer
Ruth M. Pfeiffer
CC
Chun-Ju Chiang
Chun-Ju Chiang
CW
Cheng-Ping Wang
Cheng-Ping Wang
PL
Pei-Jen Lou
Pei-Jen Lou
YC
Yu-Juen Cheng
Yu-Juen Cheng
PG
Patti Gravitt
Patti Gravitt
SD
Scott R. Diehl
Scott R. Diehl
AG
Alisa M. Goldstein
Alisa M. Goldstein
CC
Chien-Jen Chen
Chien-Jen Chen
AH
Allan Hildesheim
Allan Hildesheim
Open Access
Publisher Website
Google Scholar
Add to library
Cite
Download
Share
Download
31 March 2023
other
Published by
American Association for Cancer Research (AACR)
https://doi.org/10.1158/1078-0432.c.6519011
Abstract
Purpose: Epstein–Barr virus (EBV) infection and a family history of nasopharyngeal carcinoma (NPC) are associated with NPC risk. We examined the risk associated with EBV markers and their clinical utility to identify NPC susceptibles within high-risk NPC families.Experimental Design: We evaluated antibody titers against viral capsid antigen (VCA) IgA, EBV nuclear antigen-1 (EBNA1) IgA, and DNase among unaffected relatives of NPC cases from 358 multiplex families in Taiwan. Incident NPC cases were identified via linkage to the National Cancer Registry. Clinical examinations of 924 individuals were also done to identify occult, asymptomatic NPC. Baseline EBV serology was used to estimate NPC risk using rate ratios with 95% CI. Associated sensitivity/specificity and receiver operating characteristic (ROC) curves were calculated.Results: A total of 2,444 unaffected individuals with 15,519 person-years (6.5 years median follow-up) yielded 14 incident NPC cases (nearly 11 times the general population rate). The absolute rate of NPC among anti-EBV EBNA1 IgA seropositives using a standard positivity cutoff versus an optimized cutoff point defined by ROC analyses was 265/100,000 person-years with a 4.7-fold increased risk of NPC (95% CI: 1.4–16) and 166/100,000 person-years with a 6.6-fold increase (95% CI: 1.5–61), respectively. Sensitivity and specificity using the optimized positivity cutoff points were 85.7% and 51.2%, respectively. It is estimated that active evaluation of 49% of individuals from high-risk NPC families seropositive for this marker could lead to earlier detection of up to 86% of NPC cases. Risks associated with the other three EBV markers were weaker.Conclusions: Future efforts are needed to identify susceptibility markers among high-risk NPC families that maximize both sensitivity and specificity. Clin Cancer Res; 17(7); 1906–14. ©2011 AACR.
Keywords
RISKS ASSOCIATED
EBV MARKERS
ANTIGEN
OPTIMIZED
ANTIBODY
INDIVIDUALS FROM HIGH RISK NPC
All Articles
Open Access